1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A0B6D464E26D307E00258A2F003CB962
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-leveraging-medical-analytics-growth-areas-advanced-capabilities?opendocument
18
19opendocument
203.236.142.143
21
22
23best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Data Management and Biostatics

Leveraging Medical Analytics: Growth Areas for Advanced Capabilities

ID: 5778


Features:

6 Info Graphics

13 Data Graphics

210+ Metrics

12 Narratives


Pages/Slides: 26


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Leveraging Medical Analytics: Growth Areas for Advanced Capabilities”

STUDY OVERVIEW

In today's ever-evolving healthcare landscape, Medical Affairs organizations are at the forefront of utilizing advanced analytics to revolutionize healthcare delivery, enhance patient outcomes, and optimize resource allocation. However, this rapid transformation is not without its challenges. Variations in the pace of advancement are often attributed to resource limitations, regulatory uncertainties, and the need for specialized technical expertise to expand the realm of Medical Analytics.

Best Practices, LLC conducted this benchmarking research to probe the growth areas for building advanced Medical Analytics capabilities. The study investigates the maturity of analytics support within Medical Affairs, strategies for justifying increased investment in analytics resources, sources of expertise in Medical Analytics, and the optimal structure and resourcing of Medical Analytics groups.

This research suggests a path forward for Medical Affairs groups looking to advance their impact derived from new advanced capabilities.

KEY TOPICS

  • Average maturity of analytics support for Medical Affairs
  • Justifying investment for increased resources
  • Sources of Medical Analytics expertise
  • Effective structure of Medical Analytics groups
  • Staffing and resourcing

KEY METRICS

  • How advanced are benchmark Medical organizations in using analytics for the listed external engagement activities?
  • How advanced are benchmark Medical organizations in using analytics for the listed Medical value activities?
  • Can Medical Analytics shorten the time to adoption by HCPs for a given product?
  • Hallmarks of maturity of Medical Analytics groups
  • How are Medical Analytics internally supported and implemented within benchmark organizations?
  • Within the Medical Affairs role, how many full-time and part-time FTEs are dedicated to Medical Analytics?
  • How important are the listed factors when justifying the cost of Medical Analytics activities to the organization?

SAMPLE KEY FINDINGS

  • Signs of implantation of analytics in Medical:
    • 65% of Medical organizations have Sr. Leadership buy-in
    • 59% Use analytics to inform Medical Strategy
    • 51% Have access to data

METHODOLOGY

Best Practices, LLC engaged 41 Medical Affairs leaders from 38 leading biopharma organizations in this benchmarking research study. A range of functional leaders were targeted to capture the diverse strategies and analytical needs across the industry. Functions represented by this study include: Medical Operations, Medical Excellence, Digital & Medical Analytics, HEOR, Field Medical, Medical Communications, Medical Info, Strategic Insights, and other Senior Medical Leadership. Best Practices LLC also conducted deep-dive interviews with Medical Affairs & Analytics leaders at 9 organizations to capture additional insights.

Industries Profiled:
Health Care; Biotech; Biopharmaceutical; Pharmaceutical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Communications; Science


Companies Profiled:
Acadia Healthcare; Amicus Therapeutics; Apellis Pharmaceuticals; ASC Therapeutics; Astellas; AstraZeneca; Baxter International; Bayer; Biogen; bioMerieux; Boehringer Ingelheim; Daiichi Sankyo; Dompé; Eisai; Eli Lilly and Company; Envista; GE Healthcare; Grifols; Janssen; Kyowa Kirin; Merck Sharp & Dohme; Merz Aesthetics; Myovant Sciences; Nobel Biocare; Novartis; Novo Nordisk; Organon; Roche; Sumitomo Pharma; Sunovion; Symbiotix; Teva Pharmaceutical Industries Ltd; Thermo Fisher Scientific; Unilab; Varian; Xeris Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.